Ranpirnase

Summary

Ranpirnase (CHEMBL2108479) is a phase-3 clinical-stage enzyme; indicated across 3 conditions including mesothelioma and non-small cell lung carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Enzyme
• Indications: 3 conditions
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108479
Name	Ranpirnase
Type	Enzyme
Max phase	3

Also known as: Onconase, P-30, P-30 PROTEIN, Protein p-30, Ranpirnasa, Ranpirnase, Ribonuclease (rana pipiens), RANPIRNASE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
mesothelioma	3	MONDO:0005065	EFO:0000588
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
anogenital human papillomavirus infection	1	MONDO:0005647	EFO:0007147

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00003034	PHASE3	UNKNOWN	ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen
NCT01184287	PHASE2	WITHDRAWN	A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer
NCT02535104	PHASE1/PHASE2	COMPLETED	Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).